Latest press articles and news about NovaScan and our innovative cancer detection technology.
NovaScan, Inc. announced that it has been awarded a $3.7 million non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will support clinical work and deployment of MarginScan™ for use in breast-conserving surgery.
Read MoreNovaScan's research on rapid margin assessment using high-frequency bioelectrical impedance spectroscopy during Mohs micrographic surgery has been selected by the American Academy of Dermatology for its prestigious "Future of Dermatology" session.
Read MoreNovaScan's MarginScan™ device will be featured in a poster presentation at the Wisconsin Dermatology Society Spring Meeting, highlighting the clinical performance of MarginScan in real-time surgical margin detection.
Read MoreA new clinical trial has started employing the NovaScan Canary biopsy assessment device to detect developing pancreatic cancers in high-risk populations, focusing on patients with chronic pancreatitis who have not yet developed cancer.
Read MoreNovaScan announced the appointment of Robert W. Cook, Ph.D., former senior vice president of research and development at Castle Biosciences, and Robert Zieserl, a serial entrepreneur and venture capitalist, as advisors to assist the company as it advances towards commercialization.
Read MoreEpredia, a global leader in precision cancer diagnostics, and NovaScan announced they have signed a letter of intent for a U.S. exclusive commercial distribution agreement for MarginScan™, a medical device that supports physicians in real-time detection of non-melanoma skin cancer.
Read More